Dyne Therapeutics Enters Material Definitive Agreement
Ticker: DYN · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Dyne Therapeutics just signed a big deal, could be good or bad, need more info.
AI Summary
On June 27, 2025, Dyne Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company is a pharmaceutical preparations firm incorporated in Delaware.
Why It Matters
This filing signals a significant new contract or financial commitment for Dyne Therapeutics, potentially impacting its future operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and financial obligations, which inherently carry risks that are not fully detailed in this initial report.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- June 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1560 Trapelo Road, Waltham, Massachusetts 02451 (address) — Principal Executive Offices
- (781) 786-8230 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did Dyne Therapeutics, Inc. enter into?
The filing states that Dyne Therapeutics, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this document.
What is the nature of the direct financial obligation or off-balance sheet arrangement created?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed here.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 27, 2025.
Where are Dyne Therapeutics, Inc.'s principal executive offices located?
Dyne Therapeutics, Inc.'s principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts 02451.
What is Dyne Therapeutics, Inc.'s Standard Industrial Classification code?
Dyne Therapeutics, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Dyne Therapeutics, Inc. (DYN).